Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Other Non-Current Assets: 2016-2025

Historic Other Non-Current Assets for UroGen Pharma (URGN) over the last 7 years, with Sep 2025 value amounting to $6.8 million.

  • UroGen Pharma's Other Non-Current Assets rose 1726.76% to $6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 million, marking a year-over-year increase of 1726.76%. This contributed to the annual value of $589,000 for FY2024, which is 71.10% down from last year.
  • According to the latest figures from Q3 2025, UroGen Pharma's Other Non-Current Assets is $6.8 million, which was up 743.82% from $801,000 recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Other Non-Current Assets ranged from a high of $6.8 million in Q3 2025 and a low of $66,000 during Q1 2021.
  • Over the past 3 years, UroGen Pharma's median Other Non-Current Assets value was $1.1 million (recorded in 2024), while the average stood at $1.9 million.
  • Its Other Non-Current Assets has fluctuated over the past 5 years, first soared by 3,123.64% in 2021, then tumbled by 81.95% in 2024.
  • Quarterly analysis of 5 years shows UroGen Pharma's Other Non-Current Assets stood at $1.3 million in 2021, then surged by 109.00% to $2.7 million in 2022, then dropped by 25.62% to $2.0 million in 2023, then slumped by 71.10% to $589,000 in 2024, then surged by 1,726.76% to $6.8 million in 2025.
  • Its last three reported values are $6.8 million in Q3 2025, $801,000 for Q2 2025, and $371,000 during Q1 2025.